What is Mounjaro active ingredient and how does it work?

What does tirzepatide actually bind to, and why does that matter?

Tirzepatide is a lab-engineered peptide designed to mimic two naturally occurring gut hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Both are released when you eat. GLP-1 slows gastric emptying and sends fullness signals to the brain; GIP works alongside it, and together they also influence how cells respond to insulin.

Earlier medicines in this drug class, including the semaglutide in Wegovy, target only GLP-1. Tirzepatide targets both. That distinction is pharmacological, not marketing: the two receptors sit in different tissues, and activating them together produces effects that a single-agonist medicine cannot fully replicate. The NHS tirzepatide medicines page explains the mechanism in plain language if you want to read the patient-level summary alongside this.

In practice, the dual action reduces appetite more consistently across a wider range of people, and the gastric-emptying slowdown means food stays in the stomach longer, so you feel full from smaller portions. Neither effect is instant, most people notice appetite changes gradually over the first few weeks at a given dose. The full explanation of how Mounjaro works goes deeper into the receptor biology for those who want it.

Does the active ingredient change as the dose increases?

No. The active ingredient in Mounjaro is tirzepatide at every strength, and what changes is the concentration delivered per injection. UK-licensed doses run 2.5, 5, 7.5, 10, 12.5 and 15 mg, and the titration schedule exists to give your digestive system time to adjust rather than to introduce a different substance. The starting dose of 2.5 mg is deliberately low, its job is settling your tolerance, not maximising weight reduction.

Each pre-filled KwikPen delivers four once-weekly injections, and the prescriber decides when, or whether, to increase the dose. Most people follow a gradual upward path over several months, spending roughly four weeks at each level. Evidence suggests that many of the results seen in clinical trials come from reaching the higher doses, which is why clinical supervision throughout the titration process matters. A broader overview of tirzepatide covers the dose schedule in more detail.

A quick habit worth building: before each injection, check the pen's label for the dose printed on it. The 5 mg and 7.5 mg pens are similarly sized and easy to mix up, especially if someone else in the household is on a different strength. Thirty seconds of checking prevents a straightforward error.

How does the active ingredient explain the side effects people experience?

Most of Mounjaro's common side effects follow directly from tirzepatide's mechanism. Slowing gastric emptying is exactly what you want for appetite control, and it is also the reason nausea, burping, indigestion and altered bowel habits are the most frequently reported effects. The digestive tract is adapting to food moving through it more slowly. These effects are typically most noticeable in the first few days after a new or increased dose and tend to ease within one to two weeks for most people.

Less common but serious effects to know about include acute pancreatitis. In January 2026 the MHRA issued a Drug Safety Update noting this as an infrequent but potentially serious risk across GLP-1 medicines: if you develop severe stomach pain that radiates to your back, seek urgent medical help rather than waiting. You can report any suspected side effect at yellowcard.mhra.gov.uk.

Injection-site reactions (redness, mild swelling, itching) are also possible, which is why rotating the injection site (abdomen, thigh, upper arm) between pens is standard practice. If you want to read a fuller rundown of the side-effect profile and what to watch for, the Mounjaro treatment page at nume covers the practical detail alongside the eligibility criteria.

Who can the tirzepatide in Mounjaro be prescribed for?

The UK licence covers adults with a BMI of 30 or above, and adults with a BMI of 27 or above who have at least one weight-related condition, for example hypertension, type 2 diabetes, obstructive sleep apnoea or high cholesterol. For some ethnic backgrounds, NICE guidance applies thresholds 2.5 kg/m² lower than the standard figures. The prescriber also reviews your full medical picture: current medicines, relevant history, and any contraindications.

Tirzepatide is not licensed for people under 18, and it is not recommended during pregnancy, breastfeeding or if you are actively trying to conceive. History of conditions including medullary thyroid carcinoma or certain pancreatic and gastrointestinal disorders are factors the prescriber will ask about specifically. NICE technology appraisal TA1026 sets out the criteria that NHS prescribers follow, which gives a useful reference point even for people pursuing a private route.

If you are wondering how the evidence for tirzepatide compares across different groups, the results data page at nume pulls together the trial figures by dose. And if you are ready to see whether you might be eligible, some people also explore tirzepatide plus as part of that conversation, before checking your eligibility via a free consultation as the natural next step.